Evaluate The Clinical Effectiveness, Safety And Tolerability Of Sildenafil Used In Doses ≥20mg TID For The Treatment Of Pulmonary Arterial Hypertension
Evaluate The Clinical Effectiveness, Safety And Tolerability Of Sildenafil Used In Doses ≥20mg TID For The Treatment Of Pulmonary Arterial Hypertension
The objective of this observational study is to gain clinical insight on the actual use of
 sildenafil citrate (Revatio™) for the treatment of pulmonary arterial hypertension (PAH). The
 primary objective is to assess effectiveness and safety of sildenafil at doses ≥20mg three
 times daily for the treatment of PAH.
The study design proposed is a retrospective chart review going back five years (01 April
 2006 estimate) from the time of study initiation (31 March 2011 estimate). Within this
 five-year period, study index will occur the first time an adult patient begins sildenafil
 for the treatment of PAH for a period of at least three months. The patient has to be taking
 sildenafil at doses ≥ 20mg tid for the treatment of PAH.
Inclusion Criteria:

 -  Patients must be at least 18 years of age at study index;

 -  Patients must have a diagnosis of PAH. PAH is conventionally defined as a mean
 pulmonary arterial pressure (PAP) of > 25 mmHg and a pulmonary capillary wedge
 pressure (PCWP) ≤ 15 mmHg and a pulmonary vascular resistance (PVR) ≥ 240 dynes/s/cm-5
 at right heart catheterization;

 -  Patients must have initiated sildenafil for the treatment of their PAH; at dose ≥ 20
 mg tid within 5 years prior to study initiation

 Exclusion Criteria:

 -  Patient has known contraindications to sildenafil at study index;

 -  Patient participated in an investigational study of sildenafil treatment for PAH
 during the period beginning 6 months prior to study index